EuBiologics Co., Ltd. (KOSDAQ:206650)

Market Cap	416.49B
Revenue (ttm)	69.37B
Net Income (ttm)	-13.88B
Shares Out	36.53M
EPS (ttm)	-381.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190,470
Average Volume	159,096
Open	11,060
Previous Close	11,060
Day's Range	11,030 - 11,470
52-Week Range	9,350 - 18,800
Beta	1.22
RSI	43.64
Earnings Date	Mar 20, 2025

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits. In addition, it offers CMO services comprising of drug product production, cell bank production, and drug substance production. Further, the company provides CRMO services, including cell line development, GMP production, validation, and the ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206650

Financial Performance

In 2023, EuBiologics's revenue was 69.37 billion, an increase of 25.06% compared to the previous year's 55.47 billion. Losses were -13.88 billion, 1163.0% more than in 2022.